Prescrire Int. 2013 Feb;22(135):39.
No documented increase in overall survival with neoadjuvant trastuzumab, given the lack of trials versus chemotherapy in combination with adjuvant trastuzumab.
鉴于缺乏新辅助曲妥珠单抗与辅助曲妥珠单抗联合化疗的对比试验,尚无关于新辅助曲妥珠单抗可提高总生存率的文献记载。